Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $15.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).The analyst commented: "We’ve ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE